Clinical Trial Search

Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab — 1685.946; 5224.107…

Primary: PK: Maximum Observed Concentration (Cmax) of LY3502970 — 80.5; 67.5 nanograms per milliliter (ng/mL)

Primary: Intraclass Correlation Coefficient (ICC) for Consistency in Spinopelvic Radiographic Measurements. — .956; .956; .974; .974 Intraclass Correlation Coefficient

Primary: To Evaluate the Ability of the Ring-REI Measured by Belun Ring to Gauge the AHI Measured by PSG — 16.2; 18.5 events per hour

Primary: Clinical Global Impressions Improvement Scale as Determined by the Treating Clinician — 3.7; 3.8 score on a scale

Primary: Yale Global Tic Severity Scale - Total Tic Score — -5.6; -3.4 Score on a scale — p=<0.05

Primary: Cancer Detection Rate (CDR) Per 1,000 Screenings — 8.3; 18.3 CDR per 1,000 screenings

Primary: Event-free Survival — 76 percentage of patient

Primary: Number of Participants With Treatment Emergent Serious Adverse Events (TE-SAEs) During the Study Period. — 0; 0 Participants

Primary: Proportion of Infants Classified as Study Drug-related Safety Failures Through 2 Weeks After DTG-Discontinuation. — 0; 0; 0; 0 proportion of participants

Primary: Recruitment — 91 Participants

Primary: Visual Analog Scale (VAS) — 5; 5; 5 points (1-10; higher = worse pain) — p=0.0001

Primary: Number of Solicited and Unsolicited Adverse Events (AEs) — 17 adverse events

Primary: Cumulative Success Rate — 61; 7 implants

Primary: Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 21882.61; 27332.41 hour*picomole/liter